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ABSTRACT 
Visfatin (nicotinamide phosphoribosyltransferase) is an adipokine that performs many functions in the 
organism. It can be expressed in different tissues such as the brain, kidneys and visceral adipose tissue. 
Visfatin takes part in many molecular processes including apoptosis, inflammation, cell proliferation. It 
affects glucose metabolism and is involved in the pathogenesis of diabetes, insulin resistance, atheroscle-
rosis and obesity. Moreover, studies suggest that visfatin also may be associated with the development 
of diabetic nephropathy and retinopathy. 
The goal of the study is the assessment of the influence of different visfatin’s gene variants on the occur-
rence of late diabetic complications.
The study group consisted of 272 patients with diabetes – 139 men and 133 women from Southern Poland. 
Selected DNA fragments were amplificated and marked. Visfatin’s gene in rs4730153 was examined. The 
Real-Time PCR was conducted with fluorescence-labelled probes.
The most common genotypes were heterozygote AG- 138 patients (51%) and homozygote GG- 89 
patients (33%).
In the study group, there were 92 diabetics with retinopathy, 26 with nephropathy, 88 with neuropathy and 
103 with macroangiopathy.
It has been assessed using the c2 test that there are no differences between the variability of different 
variants of visfatin’s gene in the distribution of genotypes. According to Hardy-Weinberg’s test, the variety 
of population is maintained.
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Diabetes mellitus is a silent pandemic of the 21st 
century [1]. Its prevalence is estimated to rise from 
425 million people in 2017 to 629 million by 2045 [2]. 
Many patients with type 2 diabetes (T2DM) develop 
microvascular complications (approximately 40% of 
those develop diabetic kidney disease (DKD), which is 
a leading cause of the end-stage renal disease (ESRD) 
globally [3] and approximately 40–80% develop diabetic 
retinopathy (DR) [4] 
DKD as well as DR are often diagnosed at advanced 
stages [5]. The multifactorial pathogenesis of DKD and 
DR consists of a combination of metabolic, environ-
mental, and genetic factors [1]. A prior genome-wide 
association study (GWAS) identified genes with polymor-
phisms associated with an increased incidence of DKD 
and DR [6]. However, further studies to prove the role of 
these polymorphisms in DKD and DR occurrence and 
progression in different diabetic populations are needed, 
to guide strategies that prevent and treat DKD and DR.
Visfatin, a recently discovered adipocytokine is the 
extracellular isoform of the NAMPT enzyme. Its gene is 
located on chromosome 7 and the exact location is as 
follows: band 7q22.3, starting 106,248,298 bp, ending 
106,286,326 bp. Visfatin can cause an insulin-mimet-
ic effect in cells. As it downregulates the amount of 
glucose release from the liver, visfatin accelerates tri-
glycerides synthesis and increases glucose metabolism 
in monocytes and adipocytes. It plays an important role 
in the pathogenesis of T2DM and its complications such 
as diabetic nephropathy and retinopathy. Nevertheless, 
there are limited studies about the association between 
visfatin and diabetic complications in these diseases.
The role of visfatin in diabetic retinopathy is poorly 
understood. In humans, only one study investigated the 
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differences in visfatin concentrations between patients 
with and without diabetic retinopathy. Y. Wang et al. have 
found elevated vitreous and serum level of visfatin in dia-
betic patients with proliferative diabetic retinopathy com-
pared to these with nonproliferative diabetic retinopathy, 
without diabetic retinopathy and nondiabetic controls [7].
Patients with diabetic nephropathy show markedly 
increased serum levels of visfatin comparing to the 
non-diabetic group [8–10]. Mageswari R et al. suggest 
that visfatin level could be an index of severity of diabetic 
kidney disease. Many studies are investigating the role 
of Single Nucleotide Polymorphism (SNP) in the visfatin 
gene. It has been researched that the variations are 
involved in the pathogenesis of diabetes, obesity as 
well as may regulate plasma insulin levels and plasma 
glucose levels.
In light of the positive GWAS outcomes in relation 
to the visfatin gene and the contradictory outcomes of 
follow-up studies — as well as the lack of studies per-
formed in a Polish population — this study assessed 
the association of rs4730153 visfatin gene variants with 
DKD and DR in a group of Polish T2DM patients (the 
industrial region of Silesia, Poland).
The presented study is the first one to investigate 
the influence of SNP in the visfatin gene on diabetic 
retinopathy and nephropathy occurrence. 
Materials and methods
Materials used for this genetic study were samples 
of venous blood taken from willing subjects. All patients 
partaking in this study have signed written consent. The 
study group consisted of 272 individuals. Among them, 
139 were men and 133 women. All of these patients had 
been previously diagnosed with T2DM.
For the time needed to gather the representative 
group for research, blood samples collected from sub-
jects were stored at the proper temperature at minus 
70 Celsius degrees.
In the laboratory of Clinical Hospital 1 in Zabrze, the 
DNA material was isolated from obtained blood.  The 
next step was to prepare a proper concentration of the 
DNA which was 15 ng/μl. Then with a spectrophotom-
eter, the purity of samples was checked.
Using fluorescent-labelled TaqMan Pre-designed 
SNP Genotyping Assay probes allelic discrimination 
was performed in Roche Lightcycler 96 thermocycler. 
Alleles were marked as A in VIC and G in FAM.
Finally, statistical analysis was made to present the 
result of the study. The significance between distributions 
of genotypes and alleles, presence of diabetic retinopa-
thy, nephropathy, neuropathy and macroangiopathy were 
tested using Pearson’s c2 test. Non-parametric ANOVA 
analysis was used to examine the association of visfatin 
polymorphism in rs4730153 with the occurrence of late 
complications of diabetes mellitus. P values < 0.05 were 
considered statistically significant. The statistical software 
STATISTICA 13 for Windows (TIBCO Software Inc., Palo 
Alto, CA, USA) was used to perform all analyses.
Results
In order to analyze the dependence between vis-
fatin’s gene in rs4720153 and late complications of 
T2DM, the number of each patients’ alleles and geno-
types were profiled with clinical data and occurrence 
of complications.
Among studied patients 29 were in the healthy 
weight range (10,5%), 115 overweight (42,5%) and 
128 obese (47%) due to the WHO Body Mass Index 
(BMI) (Tab.1). The waist to hip ratio (WHR) of patients 
was also assessed with similar results: 17 patients 
with normal ratio (6,25%), 64 over-weight (23,5%) and 
191 obese (70,25%).
Genotype distribution of the patients complied with 
populational- presented heterozygote (AG) genotype 
occurred most often (51%) with AA or GG respectively 
17 and 33%. The distribution was compatible with Har-
dy-Weinberg equilibrium (Tab. 2).
Regarding treatment schedule, at the moment of 
testing 101 individuals were treated with insulin injec-
tions, 171 were taking oral medicaments and 72 were 
prescribed both of them. Hypertension was present in 
74.3% of patients (202 patients). Patients with dyslipi-
daemia stated 54,8 % (149) of all group. 
Table 1. Distribution of genotypes of visfatin’s SNP in 
rs4730153 in reference to BMI
  Normal body 
weight
Overweight Obese
AA n 4 26 15
  % 9 58 33
AG n 15 57 66
  % 11 41 48
GG n 10 32 47
  % 11 36 53
p = 0,1962
Table 2. Distribution of genotypes of visfatin’s SNP in 
rs4730153 in the research group
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Table 3. Distribution of genotypes of visfatin’s SNP in rs4730153 in reference to retinopathy occurrence 
Genotypes With retinopathy Without retinopathy p-value OR (95% CI)
N % N %
AA 13 28.89 32 71.11 - 1.00 (Reference)
AG 43 31.16 95 68.84 0.7742 1.114 (0.532–2.332)
GG 36 40.45 53 59.55 0.1914 1.672 (0.773–3.615)
AG+GG 79 34.80 148 65.20 0.4447 0.761 (0.378–1.533)
Table 4. Distribution of genotypes of visfatin’s SNP in rs4730153 in reference to nephropathy occurrence 
Genotypes
 
With nephropathy Without nephropathy p-value
 
OR (95% CI)
N % N %
AA 2 4.44 45 95.56 - 1.00 (Reference)
AG 12 8.70 126 91.30 0.3606 2.048 (0.441–9.518)
GG 12 13.48 77 86.52 0.1245 3.351 (0.716–15.673)
AG+GG 24 10.57 203 89.43 0.2165 2.542 (0.579–11.162)
Four late complications of T2DM in anamnesis 
were taken into consideration: retinopathy, nephrop-
athy, peripheral neuropathy and macroangiopathy. 
The conducted analysis provided results as present-
ed below.
Retinopathy occurred in 92 patients (33,8%). Re-
garding all of the patients, there were more without the 
retinopathy among AA and AG genotype. The above 
indicates more people with genotype GG developing 
this T2DM complication (Tab. 3).
Nephropathy was present in 26 cases (9,6%). Out 
of the patients who did not suffer from nephropathy 
51% stated AG genotype. The greatest difference can 
be seen in the GG genotype: 46 % among a group of 
occurred by retinopathy to only 31% among patients 
without this complication (Tab. 4).
Considering the next studied complication, 88 pa-
tients of the T2DM group had neuropathy, which is 
32,3% of all. With a slight difference of occurrence in 
AA genotype, the other two presents as follows: more 
non-neuropathy patients in comparison to ones with 
neuropathy in AG genotype and consequently, less 
patient without this complication than those with neu-
ropathy in GG genotype (Tab. 5).
Macroangiopathy showed most often occurrence. 
37,9 % of the studied patients (103) had already been 
diagnosed with the disease while genotype determin-
ing. In this case, the group with AA and GG genotype 
have not significantly more patients with the complica-
tion (Tab. 6).
24 (8,8%) of patients suffered from macroangiopathy 
and neuropathy altogether. Most of them presented 
GG genotype (45,8%), second AG (37,5%) and 16,7% 
AA genotype.
Only 6 (2,2%) individuals presented all of the men-
tioned complications.
We may note among all of the studied complications 
is that in the AG genotype group there are always more 
patients without the disease than with one. Exactly 
opposite we may note in GG genotype in all of the 
studied cases.
No statistically significant differences in genotype 
distribution between groups in all researched areas 
have been observed.
Table 5. Distribution of genotypes of visfatin’s SNP in rs4730153 in reference to neuropathy occurrence
Genotypes
 
With neuropathy Without neuropathy p-value OR (95% CI)
N % N %
AA 16 35.56 29 64.44 - 1.00 (Reference)
AG 37 26.81 101 73.19 0.2631 0.664 (0.324–1.360)
GG 35 39.33 54 60.67 0.6713 1.175 (0.558–2.472)
AG+GG 72 31.72 155 68.28 0.6155 0.842 (0.430–1.648)
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p-value OR (95% CI)
N % N %
AA 19 42.22 26 57.78 - 1.00 (Reference)
AG 49 35.51 89 64.49 0.4190 0.753 (0.379–1.497)
GG 35 39.33 54 60.67 0.7469 0.887 (0.428–1.838)
AG+GG 84 37.00 143 63.00 0.5103 0.804 (0.420–1.540)
Discussion
The study aimed to investigate the correlation 
between different variants of the visfatin gene in rs 
4730153 and the occurrence of late complications of 
T2DM in the population of Southern Poland. The authors 
wanted to assess whether the studied SNP of the visfatin 
gene is associated with an increased risk of developing 
late complications of diabetes. 
T2DM is a growing problem nowadays; in 2013 there 
were 3 million patients diagnosed with diabetes in Po-
land [11]. What is more, 30% of patients diagnosed with 
myocardial infarction have also diabetes; one in seven 
patients with newly diagnosed diabetes will develop 
acute coronary syndrome in the next 10 years, 60% 
of patients with a duration of diabetes of more than 
15 years have retinopathy and 15% – nephropathy [12]. 
As has been mentioned, the level of proinflam-
matory visfatin is elevated in patients with diabetes 
mellitus. Many studies indicate that visfatin may lead 
to vascular disorders in different mechanisms: visfatin 
ability to induce MMP-9 and nuclear factor-kB which 
are involved in the instability of atherosclerotic plaque. 
Moreover, visfatin may be engaged in endothelial 
dysfunction [13]. It has been shown that in diabetic mac-
roangiopathy the level of serum visfatin is significantly 
lower in comparison to patients with non-complicated 
diabetes. Additionally, the serum level of visfatin can be 
negatively correlated with the lipid profile [14]. 
It was described that visfatin as an adipokine with 
proangiogenic features may take some role in the 
pathogenesis of diabetic retinopathy. In patients with 
diabetic retinopathy, the concentration of visfatin in 
serum and vitreous is elevated and correlated with the 
severity of the disease [15]. 
It has been reported that visfatin may stimulate the 
expression of endothelial nitric oxide in renal cells in 
patients with diabetic nephropathy. This observation 
seems to be confirmed by the fact that patients with 
diabetic nephropathy have an increased level of visfa-
tin in serum [16] especially in the IV stage of disease 
in comparison to stage III [17]. The level of visfatin in 
serum can predict the severity of diabetic nephropathy. 
There are only several pieces of research that 
investigated the role of visfatin polymorphism in 
rs4730153. One of them indicates that there is no as-
sociation between T2DM and studied SNP, however, 
the ratio visceral/subcutaneous visfatin expression is 
correlated with visfatin polymorphism in rs4730153 [18]. 
Other studies note the role of rs4730153 in the 
pathogenesis of obesity; it was also described that 
plasma visfatin level is increased in patients with obesity. 
One study indicates that genotype AA in rs4730153 of 
visfatin gene may decrease the risk of cardiovascular 
disorders both in patients with normal body weight 
and with obesity. Variant AA of the rs4730153 is relat-
ed to fasting blood glucose, fasting blood insulin and 
HOMA-IR (homeostasis model assessment-insulin 
resistance) [19]. 
Other research was carried out on Chinese obese 
children taking part in the aerobic exercise training pro-
gram. It has observed statistically significant differences 
in the level of triacylglycerols (TG) and HOMA-β value 
before and after the exercise programme according to 
genotype in rs4730153. Genotype GG seems to reduce 
TG level and increase sensitivity to insulin-induced by 
exercises [20]. 
There are contradictory data on the association 
between rs4730153 and BMI; some studies suggest 
that there is no association between rs4730153 and BMI 
[18], but on the other hand another one shows a bor-
derline significant correlation between rs4730153 and 
decreased BMI [21]. 
The presented study was carried out since there 
are no other available studies about the role of visfatin 
polymorphism in rs4730153 in long term complica-
tions of diabetes mellitus. This study is the first one 
that investigated the association between visfatin 
polymorphism and late complications of diabetes. The 
authors had not observed any statistically significant 
association between different variants of the visfa-
tin gene in rs 4720153 and the occurrence of late 
complications of diabetes. However, the duration of 
diseases and intensity of glycemic control influence 
strongly the development of diabetes complications 
[22]. Also, the disproportion in the number of patients 
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with/without specific complications could have affect-
ed the results. 
This study had some limitations: the concentration 
of visfatin in serum was not measured; the expression of 
visfatin by measuring visfatin mRNA was also not exam-
ined, so it could not have been assessed how studied 
SNP influences visfatin expression. Further studies with 
a complete assessment of visfatin expression not only 
in serum but also in organs involved in diabetic com-
plications are necessary to assess the role of visfatin 
polymorphism in rs4730153 in the development of long 
term complications of diabetes mellitus. 
In comparison to other visfatin’s SNPs, rs4720153 is 
yet to be widely researched. 
Conclusions
Collected data showed that SNP in rs4730153 of 
visfatin using c2 test does not show a statistically sig-
nificant correlation in any of the late complications of 
T2DM. All of the complications were present more often 
in heterozygote patients (AG) which may result from 
the largest group of patient with the genotype. Most 
tested patients were obese and suffered already from 
hypertension and dyslipidaemia. 
Because of a quite small group and not much of 
any other research on this polymorphism, further study 
is needed to know the role of SNP of visfatin in T2DM 
late complications.
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